Compass Pathways CEO signals cautious psychedelic therapy rollout ahead of FDA review

Compass Pathways CEO indicates the company will prioritize a measured, phased approach to commercializing its psychedelic therapy as it approaches regulatory review this year. The statement suggests management is tempering expectations for rapid market expansion, likely reflecting regulatory and clinical uncertainties. This matters as it signals a potentially slower revenue ramp for a key player in the emerging psychedelics sector.